Adrenal disease

Long‐acting porcine ACTH stimulated salivary cortisol reduces the overdiagnosis of adrenal insufficiency compared to serum cortisol in cirrhosis liver

Clin Endocrinol (Oxf)Published Cross-sectional study

Authors' conclusion

Long-acting porcine ACTH stimulated salivary cortisol reduces the overdiagnosis of adrenal insufficiency compared to serum cortisol in cirrhosis liver. Stimulated salivary cortisol is a promising investigation for evaluation of adrenal function in cirrhosis and more studies are required for its further validation before clinical use.

Study context

Population
Noncritical patients with cirrhosis at different stages and healthy controls; serum and salivary samples at baseline and 1 and 2 h after LA-ACTH injection135 cirrhosis, 45 controls
Participants
45 / 45 / 45 / 45
Exposure
LA-ACTH-stimulated salivary vs serum cortisol for diagnosing adrenal insufficiency (AI) in cirrhosis
  • Child An = 45
  • Child Bn = 45
  • Child Cn = 45
  • Controlsn = 45reference
Outcome
Prevalence of true AI by LA-ACTH-stimulated serum and salivary cortisol
Follow-up
2 h after LA-ACTH

Main finding

As reported in the abstract

AI diagnosis in cirrhosis (cut-offs: 2.5th centile in controls, serum 19.8 and saliva 0.97 μg/dL) · 2 h

AI by stimulated salivary cortisol cut-off

6

4.4%

Inadequately stimulated serum cortisol

39

28.9%

Observational data: associations, not effects.

Further findings

2-h stimulated salivary cortisol

Steroid replacement therapy required

Symptomatic patients requiring steroid replacement
3

Risk factor for misdiagnosis of AI by serum cortisol testing

Hypoalbuminemia identified as a major risk factor

Original publication

Long‐acting porcine ACTH stimulated salivary cortisol reduces the overdiagnosis of adrenal insufficiency compared to serum cortisol in cirrhosis liver. Clin Endocrinol (Oxf). Published 18 February 2024. doi:10.1111/cen.15030

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.